
































Department of Pathology 
Haartman Institute 
Faculty of Medicine 





          
 
 
Target Cell Topography  
and Cytoskeletal Reorganization 















To be presented and publicly discussed with the permission of the Faculty of 
Medicine, University of Helsinki, in the Small Lecture Hall of the Haartman 










Docent Tuomo Timonen, M.D., Ph.D. 
Meilahti Laboratories of Pathology, HUSLAB 
Helsinki University Central Hospital 
Department of Pathology, Haartman Institute 




Docent Sampsa Matikainen, Ph.D. 
Unit of Excellence for Immunotoxicology 
Finnish Institute of Occupational Health 
Helsinki, Finland 
and 
Professor Marko Salmi, M.D., Ph.D. 
MediCity Research Laboratory 




Professor Olli Silvennoinen, M.D., Ph.D. 
Institute of Medical Technology 




Front Cover Illustration: Two NK cells adhering to a target cell expressing early viral 
protein (nsP1) that sensitizes the target cell to NK cell killing (SEM photo by Pekka 
Kujala, and modified by Tuula Helander (manuscript). 
 
ISBN 978-952-92-6884-9 (paperback) 
ISBN 978-952-10-6097-7 (PDF) 
http://ethesis.helsinki.fi 
 











































      “Express Yourself or Die” 





















List of Original Publications................................................................   7 
 




Review of the Literature...................................................................... 12 
   Introduction......................................................................................... 12 
   1. Cytotoxic cells of the immune system............................................. 12 
   2. Brief overview of NK cells.............................................................. 14 
 2.1 Morphology........................................................................... 15 
2.2 Surface markers..................................................................... 15 
2.3 NK cell activation................................................................. 16 
2.4 MHC class I specific receptors............................................. 17 
   3. Cytotoxic mechanism...................................................................... 19 
 Granule release ! perforin and granzymes....................... 20 
   4. Target cell recognition.................................................................... 21 
4.1 Binding to a target ! first requirement, but is it sufficient 
      for triggering?....................................................................... 22 
LFA-1 on the surface of effector cells............................. 22 
ICAM-2 on target cells.................................................... 23 
CD2!LFA-3 pathway...................................................... 24 
4.2 Triggering of lysis................................................................. 25 
4.3 Immunological synapse ! the time and place of decision.... 26 
Actin cytoskeleton........................................................... 27 
  Ezrin, a linker protein between plasma membrane and 
  actin cytoskeleton............................................................ 27 
   5. Virus infections and NK sensitivity................................................ 28 
 
Aims of the Study................................................................................. 29 
 






Results and Discussion............................................................................ 35 
   1. IL-2-activated NK cells and human chromosome 6 (I) .................... 35 
1.1 Mouse/human cell hybrids as target cells................................ 35 
1.2 Binding of non-activated and IL-2-stimulated PBL to  
      mouse/human hybrid cells........................................................ 35 
1.3 Cytotoxicity of non-activated and IL-2 stimulated PBL  
      to 6-hybrid cells....................................................................... 37 
1.4 Expression of human MHC class I and II antigens.................. 37 
   2. ICAM-2 and cytoskeletal ezrin in NK cell activity (II)..................... 38 
2.1 Adhesion molecules................................................................. 38 
2.2 Expression and distribution of mouse ICAM-2, and  
      cell polarization........................................................................ 39 
2.3 Colocalization of membrane-cytoskeletal linker protein  
      ezrin and ICAM-2.................................................................... 39 
2.4 Ezrin regulating the cellular distribution of ICAM-2 
      and NK sensitivity.................................................................... 41 
   3. Viral early protein nsP1 in NK cell killing (III)................................. 43 
 3.1 Background.............................................................................. 43 
3.2 Viral non-structural proteins translated early in  
      the virus cycle.......................................................................... 43 
   Semliki Forest Virus........................................................... 44 
Nonstructural proteins of SFV............................................ 44 
3.3 Viral replicase protein nsP1 sensitizes targets for NK activity 45 
3.4 Deletion of membrane-binding properties of nsP1  
      inhibited the killing .................................................................. 45 
3.5 Binding of NK cells to nsP1 induced filopodia-like structures 46 
3.6 The CD2!LFA-3 pathway in nsP1-induced NK killing.......... 46 
3.7 Colocalization of nsP1 and ezrin.............................................. 47 
 



























List of Original Publications 
 
 
This thesis is based on the following original publications, which are referred to in 
the text by their Roman numerals (I-III). The original publications have been 
reprinted with the kind permission of the copyright holders. Some unpublished data 
have also been included in the thesis.  
 
 
  I Helander, T., Timonen, T., Kalliomäki, P. & Schröder, J. 1991. 
Recognition of chromosome 6-associated target structures by human 
lymphokine-activated killer cells. J. Immunol. 147: 2063-2067.  
 
 II Helander, T.S., Carpén, O., Turunen, O., Kovanen, P.E., Vaheri, A. & 
Timonen, T. 1996. ICAM-2 redistributed by ezrin as a target for killer 
cells. Nature, 382: 265-268. 
 
III Helander, T.S., Auvinen, P., Kujala, P, Vaheri, A., Kääriäinen, L. & 
Timonen T. Viral early protein nsP1 sensitizes target cells to NK killing 























ADCC antibody-dependent cellular cytotoxicity 
APC  antigen presenting cell 
CD  cluster of differentiation 
CISS  chromosomal in situ suppression hybridization 
CMV  cytomegalovirus 
CTL  cytotoxic T lymphocyte 
DC  dendritic cell 
ERM  ezrin - radixin - moesin  
F-actin filamentous actin  
FITC  fluorescein isothiocyanate 
HA  influenza virus hemagglutinin 
HLA  human leukocyte antigen 
HSV  Herpes Simplex Virus 
ICAM  intercellular adhesion molecule 
IFN  interferon 
Ig  immunoglobulin 
IL  interleukin 
ITAM  immunoreceptor tyrosine-based activatory motif 
ITIM  immunoreceptor tyrosine-based inhibitory motif 
KIR  killer cell immunoglobulin-like receptor 
LAK  lymphokine activated killer 
LFA  lymphocyte function-associated antigen 
LGL  large granular lymphocyte 
mAb  monoclonal antibody 
MHC  major histocompatibility complex 
MICA, B major histocompatibility complex class I  

















NCR  natural cytotoxicity receptor 
NK  natural killer 
nsP  nonstructural protein(s) 
PBL  peripheral blood lymphocyte(s) 
p.i.  post infection 
SFV  Semliki Forest Virus 
SEM  scanning electron microscopy 
TCR  T cell receptor 
TEM  transmission electron microscopy 
Th  helper T lymphocyte  
TNF  tumor necrosis factor 
TRITC tetramethyl rhodamine isothiocyanate 
Ts  suppressor T lymphocyte 















Cell-mediated cytotoxicity is a highly organized multifactorial process inducing 
target cell death through cytotoxic effector cells. Its most important function is to 
remove abnormal or infected cells in order to prevent the development of 
malignancies and to eliminate intracellular pathogens.  
 
Natural killer (NK) cells directly recognize and kill transformed or virus-infected 
cells without prior sensitization. NK cell functions, cytotoxicity and cytokine 
production, are regulated by a balance between negative and positive signals 
initiated after the engagement of cell surface inhibitory and activating receptors 
that bind to specific ligands on altered and normal cells. 
 
We have studied both virus-infected and tumor cells in order to identify the target 
structures involved in triggering NK activity. 
 
To investigate the target cell sensitivity and the structures involved in NK cell 
activity, mouse/human cell hybrids containing various human chromosomes were 
used as targets. The human chromosome responsible for activating NK cell killing 
was identified to chromosome number 6. The chromosome 6-hybrid cells were 
resistant to non-activated NK cells but were very efficiently bound to and killed 
by interleukin 2-activated (IL-2) killer cells. The hybrids containing several other 
human chromosomes, but not number 6, were not sensitive to any killer activity. 
The results suggest that activated NK cells recognize ligands that are encoded on 
human chromosome 6. 
 
The binding and cytotoxicity of NK sensitive human chromosome 6-hybrids were 
effectively inhibited by antibodies against lymphocyte function-associated 
antigen, LFA-1 (adhesion receptor on effector cells). We showed that the ligand 
on the target cell side was intercellular adhesion molecule 2 (ICAM-2). There was 
no difference in the level of expression of ICAM-2, however, but a drastic 
difference was seen in the distribution of the molecule: ICAM-2 was evenly 
distributed on the surface of the NK-resistant cells, but almost totally redistributed 
to the tip of uropods, bud-like extensions, which were absent from the parental 
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cells. ICAM-1, another ligand of the LFA-1 molecule, was evenly distributed in 
both cell lines.  
 
The results demonstrate that human chromosome 6 induces accumulation of 
ICAM-2 onto the tips of uropods present in NK cell-sensitive hybrids. 
Interestingly, the gene coding for the cytoskeletal linker protein ezrin has been 
localized to the long arm of human chromosome 6. The results of both 
immunoblotting and immunofluorescence assays showed that 6-hybrids expressed 
both mouse and human ezrin, and there was a colocalization of ezrin and ICAM-2 
in the uropods. Furthermore, the transfected human ezrin into NK cell-resistant 
cells induced uropod formation, ICAM-2 and ezrin redistribution to newly formed 
uropods, and sensitized target cells to NK cell killing. 
 
The results shed light on a novel mechanism of target cell recognition by killer 
cells: target structures are normal structures, already present on the surface of 
normal (healthy) cells, but in pathological conditions structures are concentrated 
into biologically active foci due to aberrant cytoskeletal interactions.  
 
NK cells are central players in the defence against virus infections by the secretion 
of antiviral cytokines, such as interferon gamma (IFN-"), or by the direct lysis of 
virus-infected cells. They inhibit the spread of infection, allowing time for specific 
immune responses to develop. Surprisingly little data are available on the direct 
cytotoxicity of virus-infected targets by NK cells.  
 
Semliki Forest virus (SFV) was used as a model to study the viral structures that 
could be central in NK activity. The SFV-specific non-structural proteins (nsP1-4) 
translated early in the virus cycle were transfected in NK-resistant cells using 
vaccinia virus expression vector, which allows efficient and rapid synthesis of 
plasmid-encoded proteins. Viral gene nsP1 alone efficiently sensitized target cells 
to NK activity. NsP1 localized to the cytoplasmic surface of the viral induced 
filopodia-like extensions. The tight membrane association of nsP1 seems to be 
critical in the triggering of NK killing, since the nsP1-mutant devoid of 
membrane-binding sequences did not sensitize transfectants to NK activity. It 
seems that NK cells recognize virus-infected cells at a very early stage, long 
before any viral structural proteins are produced. 
 
The present SFV-model, which shows that structural changes are associated with 
NK sensitivity, suggests that in viral infections NK cells react to rapid changes in 
membrane topography, and thus facilitate the generation of a more efficient T cell 










Review of the Literature 
 
Introduction 
The immune system has to recognize and destroy abnormal or infected cells to 
maintain homeostasis. The immune response is traditionally divided into two 
broad systems which provide innate and adaptive immunity. These systems ensure 
protection to potentially pathogenic microorganisms, such as viruses, bacteria, 
fungi and parasites. If infection occurs, usually the pathogen is rapidly recognized 
and destroyed, and long lasting immunity ensues. An adaptive immune response 
provides specific immunity, but the first line defence against pathogens is the 
innate system. Natural killer (NK) cells comprise a unique subset of immune cells 
that have long been considered as innate immune cells.  
 
Tumors are formed by cells that have overcome normal growth regulation 
mechanisms. Therefore the ability to distinguish normal, healthy cells from 
abnormal ones is a key element of selectively attacking tumor cells. NK cells have 
various receptor systems designed to recognize abnormal cells. Besides killing the 
altered cells, the target cell recognition can also induce NK cells to secrete several 
cytokines and chemokines thus regulating both innate and adaptive immune 
response (Cooper et al., 2001). 
 
1. Cytotoxic cells of the immune system 
Many unique cell types respond to pathogen-derived molecules and play key roles 
in combating infections or otherwise deranged cells. Innate immune cells, such as 
macrophages and dendritic cells (DC), directly kill the pathogenic micro-
organisms through phagocytosis, or produce cytokines that aid elimination of the 
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pathogens and instruct adaptive immune response (Akira et al., 2006; Medzhitov, 
2007). Immunity against the pathogens depends on the recognition of pathogen-
derived structures in the plasma membrane or in the cytosol by receptors that are 
collectively known as pattern-recognition receptors (PRR). Of these, the Toll-like 
receptors (TLR) are best characterized (Diacovich and Gorvel, 2010). These 
innate receptors are evolutionary conserved and are encoded in the germline of 
multicellular organisms (including insects and jawed vertebrates). TLR are 
broadly expressed on leukocytes, and some receptors are also expressed on human 
NK cells (e.g. TLR1, TLR6 and TLR9) suggesting that they may also participate 
in triggering immune responses (Hornung et al., 2002). 
 
The other group, adaptive immune cells, such as T and B lymphocytes, react with 
specificity to peptides derived from pathogens, expand clonally, and usually after 
a week of infection the immune response takes place. T cells can be roughly 
divided into two main classes: cytotoxic T cells (CTL) kill virus-infected cells, 
and helper T cells (Th) activate other innate and adaptive immune cells. B cells, 
when activated and differentiated into plasma cells, secrete pathogen-specific 
antibodies. Despite many similarities between the innate and adaptive immune 
response (activation, proliferation, cytokine production), the critical distinction is 
the formation of immunologic memory by the adaptive immune cells.  
 
The cytotoxic activity is efficiently performed by NK cells and CTL. Regardless 
of acting upon target cells in the same way ! inducing programmed cell death, 
called apoptosis ! the mechanisms of lymphocyte-mediated cell recognition are 
different. CTL kill target cells by processing and presenting specific antigens 
through the major histocompatibility complex (MHC) class I molecules. In 
contrast, NK cells destroy target cells in which the expression of MHC is reduced 
or deficient. Thus, NK cells can recognize alterations that cannot be detected by 
the peptide/MHC-specific T cells. NK cells detect loss of expression of self-MHC 
protein: this concept of recognition is known as “missing self hypothesis” (Fig. 1) 
(Ljunggren and Karre, 1985; Ljunggren and Karre, 1990; Karre, 1995; Karre, 
2008). Although human red blood cells do not express MHC class I molecules, 







Figure 1. "Missing-self" hypothesis. An NK cell does not lyse the healthy (autologous) 
target cell that expresses the appropriate self-MHC class I alleles which are recognized 
by inhibitory receptors (A). An NK cell eliminates the target cell because the critical "self" 
proteins are absent from the target cell surface (e.g. due to viral infection or 
transformation) (B). Modified from Kumar & McNerney (2005). 
 
 
During virus infection, T cells can recognize viral peptides presented on MHC 
class I leading to elimination of virus-infected cells. However, some viruses (such 
as cytomegalovirus, CMV) inhibit all host protein synthesis, and then also the 
MHC class I protein synthesis is blocked (Lanier, 2008). Thus the NK cells are no 
longer inhibited through their MHC-specific receptors, but are ready to activate 
their cytolytic machinery. Some viruses (such as HIV) are also able to prevent 
export of MHC class I molecules, which allows the infected cells to evade 
recognition by CTL, although they are still sensitive for NK cell killing (Swann et 
al., 2001). 
 
According to the "missing self" hypothesis, NK cells recognize and eliminate cells 
that fail to express self MHC class I molecules. However, there are also NK-
sensitive, malignant cells that express MHC class I molecules, as well as NK-
resistant tumor cells with diminished expression of MHC I (Garcia-Lora et al., 
2003; Bubenik, 2004; Aptsiauri et al., 2007). 
 
2. Brief overview of NK cells 
NK cells were first characterized more than 35 years ago. Their discovery was 
based on their ability to "spontaneously" kill certain tumor cells (Herberman et al., 
1975; Kiessling et al., 1975; Kiessling and Wigzell, 1979). They serve in the first 
line of defence against a variety of infections. This is best demonstrated by a 
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patient who had complete and selective NK cell deficiency, and suffered from 
continuous, severe herpes virus infections that were eventually fatal (Biron et al., 
1989; Lodoen and Lanier, 2006; Bustamante et al., 2008). NK cells are mainly 
generated in bone marrow, although other organs such as spleen, fetal liver, lymph 
nodes and thymus have been proposed to engage in NK cell development (Freud 
and Caligiuri, 2006; Huntington et al., 2007). 
 
2.1 Morphology 
Morphologically NK cells are large granular lymphocytes (LGL) (Timonen et al., 
1981). Their azurophilic granules are rich in cytolytic enzymes, such as perforin 
and granzymes (Timonen et al., 1981; Trinchieri, 1989). Also some activated CTL 
may have LGL morphology, but NK cells are clearly not T cells even though they 
sometimes share some effector functions and surface molecules (Lanier et al., 
1986c).  
 
2.2 Surface markers  
Human NK cells express several markers associated also with other cells, but they 
closely resemble T cells. They express CD56, which is also found on a fraction of 
T cells, but they do not express the T-cell receptor complex (TCR/CD3) nor do 
they rearrange the TCR genes (Lanier et al., 1986a). 
 
CD56 is a molecule derived from alternative splicing of the gene encoding the 
neural cell adhesion molecule (NCAM) involved in nervous system development 
and cell-cell interactions (Hercend et al., 1985; Lanier et al., 1986b; Cunningham 
et al., 1987; Rutishauser et al., 1988; Lanier et al., 1989b). NK cells do not express 
the CD3 components, typical for T cells, except for the CD3 zeta chain, which is 
associated with CD16 (Fc"RIII) and other NK cell activation receptors (Lanier et 
al., 1989a). CD3# is required for the development of T cells but apparently not of 
NK cells. NKT cells are defined as T cells bearing a unique invariant T cell 
receptor (TCR) plus NK1.1, whereas NK cells have only the latter surface marker 
(Matsumoto et al., 2000). 
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Subsets of NK cells can be distinguished by the surface density expression of 
CD56, as well as the presence and absence of CD16 (Caligiuri, 2008). Most of the 
peripheral blood NK cells are CD56dim, which are rare in lymph nodes. CD56dim 
cells are functionally almost exclusively cytotoxic (Robertson and Ritz, 1990). 
CD56bright NK cells are predominant in secondary lymphoid tissues (lymph nodes, 
tonsils) and preferentially produce many cytokines. Notably, even the CD56dim is 
generally related to cells having natural killing capacity; the marker itself is not 
required for target recognition. CD56-positive NK cell subsets show differences 
also in their NK receptor repertoires (Lanier, 1998). CD56bright cells express high 
levels of C-type lectin-like CD94/NKG2 family with only few of the cell 
populations expressing killer-cell immunoglobulin-like receptors (KIR). Cytotoxic 
CD56dim NK cells express strongly both KIR and C-type lectin-like receptors 
(Farag et al., 2002). The phenotype of ‘resting’ NK cell resembles the effector 
CD8+ T cell: many NK receptors are expressed on CTL only after their 
maturation to effector or memory cells, whereas they are constitutively present on 
NK cells (Vivier and Anfossi, 2004).  
 
2.3 NK cell activation 
Lymphokine-activated killer (LAK) cells were first described by Rosenberg et al. 
in the early 1980s (Grimm et al., 1982; Grimm et al., 1983; Mule et al., 1984). 
When attempting to grow lymphoid cells that infiltrate solid tumors, they 
discovered that such cells, when incubated with the cytokine interleukin-2 (IL-2), 
acquired the ability to lyse a wide range of autologous and allogeneic tumors, 
although they spared normal non-malignant cells. In the ‘80s and ‘90s, a number 
of preclinical trials had shown that when LAK cells and IL-2 were infused into 
patients with metastatic cancer, impressive tumor regression could occur, and in 
some cases even tumor eradication. Clinical data have supported the contention 
that although NK and LAK activities seem to be similar with regard to their lytic 
properties, their mechanisms of target cell recognition and lytic attack appear to 
be quite different. LAK immunotherapy has been shown to have a potential to 
eradicate tumor cells in various forms of cancer (e.g. ovarian, malignant 
melanoma, breast and renal cell carcinoma) (Savas et al., 1996; Brinkmann et al., 
1999; Savas et al., 2006). 
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NK cell response can be triggered within minutes, without requiring transcription, 
translation, or cell proliferation. As shown by Stetson et al., NK cells 
constitutively express prestored transcripts for interferon gamma (IFN-") that are 
immediately available to initiate cytokine synthesis upon activation (Stetson et al., 
2003). NK activity can be increased up to 100-fold with cytokines, e.g. interferons 
alpha (IFN-$) and beta (IFN-%), and IL-12. These cytokines are produced early in 
many infections, and in addition to stimulating NK cytotoxicity they induce the 
production of other cytokines such as IFN-" in NK cells themselves. CD56bright 
NK cells produce a series of cytokines, including IFN-", TNF-$, TNF-%, GM-CSF 
(granulocyte-macrophage colony stimulating factor), and IL-10 upon activation 
(Yokoyama et al., 2004). This suggests that NK cytokine production is also 
important in the initiation of acquired immune response. This makes NK cells 
well suited for early and immediate defense.  
 
2.4 MHC class I specific receptors 
For almost two decades NK cell killing has often been referred to as "non-MHC-
restricted" cytotoxicity, in order to distinguish innate NK-mediated cytotoxicity 
from adaptive T cell function. This interpretation has recently been questioned, 
since NK cells express MHC class I-specific receptors, which have the ability to 
inhibit or activate NK cell function. There is no evidence that NK cells recognize 
MHC class II molecules. The data are based mostly on the analysis of class II-
deficient mice, and on in vitro functional studies using target cells expressing 
MHC class II (Ohlen et al., 1995; Hayakawa and Smyth, 2006). 
 
NK cell effector functions are regulated by a balance between activating and 
inhibitory signals through a wide repertoire of receptors (Tables 1a and b). Down-
regulation of self-MHC class I molecules, up-regulation of ligands for activating 
receptors, or expression of pathogen-associated molecules (stress signals) can be 







Table 1a.  Activatory human NK cell receptors and their ligand specificities. 
Some candidate receptors (such as LFA-1) are also included. Other receptors 
such as growth factors and chemokines are not shown. Modified from (Lanier, 
2005; O'Connor et al., 2007; Bryceson and Long, 2008; Cheent and Khakoo, 
2009).  
 
Activating Receptor  Ligand       Signaling   
KIR2DS1   HLA-C2    DAP12-ITAM 
KIR2DS2   HLA-C1    DAP12-ITAM 
KIR2DS3   unknown    DAP12-ITAM 
KIR2DS4   HLA-C    DAP12-ITAM 
KIR2DS5   unknown     DAP12-ITAM 
KIR3DS1   HLA-Bw4?    DAP12-ITAM 
KIR2DL4   HLA-G (soluble)   ITIM, Fc&RI" 
NKG2D   MICA, -B; ULBP   DAP10 
NKG2E   HLA-E     ? 
NKp30 (CD337)  BAT3     TCR#/FcR"-ITAM 
NKp44 (CD336)  cellular unknown, viral HA  DAP12-ITAM 
NKp46 (CD335)  cellular unknown, viral HA  TCR#/FcR"-ITAM 
CD16 (FcR"III)  Fc of IgG    TCR#/FcR"-ITAM 
DNAM-1 (CD226)  Necl-5 (CD155, PVR), nectin-2 (CD112) ? 
NKp80   AICL      ? 
CD59    unknown     ? 
NTB-A   NTB-A     ? 
2B4 (CD244)   CD48     SAP 
CD2    LFA-3 (CD58)    ? 
LFA-1 (CD11/CD18)  ICAM-1 , -2, -3, -4, -5   ? 
TLR    PAMPs, dsRNA    ? 
CD96 (Tactile)  Necl-5 (CD155)    ? 
CD44    HA, others?     ?  
CD94/NKG2C  HLA-E    DAP12-ITAM 
             
KIR, killer cell immunoglobulin-like receptor (CD158); HLA, human leukocyte antigen; 
DAP12, ITAM-bearing transmembrane adaptor; ITAM, immunoreceptor tyrosine-based 
activation motif; ITIM, immunoreceptor tyrosine-based inhibitory motif; NKG2, NK cell 
group 2 transmembrane receptor; MIC, MHC class I-chain-related molecule; ULBP, 
UL16-binding protein; BAT3, HLA-B-associated transcript 3; NKp, NK cell specific 
receptor; TCR, T cell receptor; HA, hemagglutinin; DNAM-1, DNAX accessory molecule-
1; Necl-5, nectin-like molecule-5; AICL, activation-induced C-type lectin; PVR, poliovirus 
receptor; NTB-A, NK-T-B antigen (self-ligands); SAP, signaling lymphocytic activation 
molecule (SLAM)-associated protein; LFA, lymphocyte function-associated antigen; 
ICAM, intercellular adhesion molecule; TLR, toll-like receptors; PAMPs, pathogen-
associated molecular patterns; dsRNA, double-stranded RNA; Tactile, T cell-activated 
increased late expression. • NK cells express three ITAM-containing adapter proteins: 
Fc&RI", CD3#, and DAP10 (Anderson et al., 1989; Hibbs et al., 1989; Lanier et al., 
1998). CD94/NKG2C and KIR molecules lacking ITIMs and having a charged residue in 
their transmembrane domains are likely to pair with the DAP12 signaling adapter 
molecule. KIR2DL4 is an exception: it has an ITIM in its cytoplasmic domain and is 
associated with the FcRI" signaling adapter. 
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Table 1b.  Inhibitory human NK cell receptors and ligand specificities. 
Modified from (Lanier, 2005; O'Connor et al., 2007; Bryceson and Long, 2008; 
Cheent and Khakoo, 2009). 
 
Inhibitory Receptor  Ligand    Signaling   
KIR2DL1   HLA-Cw2, -4, -5, -6      ITIM 
KIR2DL3 (2DL2)  HLA-Cw1, -3, -7, -8      ITIM 
KIR2DL5   unknown       ITIM 
KIR3DL1   HLA-Bw4       ITIM 
KIR3DL2   HLA-A3, A11       ITIM 
KIR3DL3   unknown       ITIM 
CD94/NKG2A  HLA-E       ITIM 
ILT2 (CD85j, LILRB1) HLA-A, B, C, E, F, G; CMV UL18    ITIM 
ILT4 (CD85d, LIR2)  HLA           ? 
LAIR-1 ?   collagens?       ITIM 
Sigleg-7   sialic acid          ? 
MAFA    cadherins          ? 
NKR-P1 (CD161)  LLT1        ITIM 
CEACAM1 (CD66a)  CEACAM1         ? 
             
KIR, killer cell immunoglobulin-like receptor (CD158); HLA, human leukocyte antigen; 
ITIM, immunoreceptor tyrosine-based inhibitory motif; NKG2, NK cell group 2 
transmembrane receptor; ILT, immunoglobulin-like transcript; LILR/LIR, leukocyte 
immunoglobulin-like receptor; CMV UL18, cytomegalovirus encoded glycoprotein; LAIR-
1, leukocyte-associated immunoglobulin-like receptor-1; MAFA, mast cell function-
associated antigen; NKR-P1, natural killer cell receptor protein 1; LLT1, lectin-like 
transcript 1; CEACAM, carcinoembryonic antigen-related cell adhesion molecule. • 
Inhibitory KIR, ILT2, and CD94/NKG2A contain ITIMs in their cytoplasmic domains.  
 
The same molecule may sometimes serve both a triggering and an inhibitory 
ligand (Tables 1a and b). The reason for the same structure being activating as 
well as inhibitory may in part relate to the density of the molecules on the target 
cell, and to the activatory or costimulatory molecules that associate with the 
cytoskeletal proteins. 
 
3. Cytotoxic mechanism 
Cytolytic killing is a major effector mechanism in the elimination of tumor cells 
or virally infected cells. NK cells and CTL, despite their differential immune 
recognition, both have the same lytic mechanism of action, i.e. the cytolytic 
granule release.  
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NK cells can detect target-cell-bound antibodies by a mechanism called antibody-
dependent cellular cytotoxicity (ADCC) (Perussia, 1998). The low-affinity 
receptor for IgG, CD16 expressed on NK cells, mediates ADCC and signals 
through adaptors containing a cytoplasmic immunoreceptor tyrosine-based 
activatory motif (ITAM), which activates the cytotoxic machinery.  
 
The mAbs used for anti-cancer therapies can effectively stimulate NK cell activity 
through CD16. Freshly isolated NK cells are poorly cytotoxic, but their 
cytotoxicity is strongly enhanced by using mAb-coated target cells. It seems that 
therapeutic mAbs against tumors rely on the ability of NK cells to sequentially kill 
numerous target cells (serial killing). It is noteworthy that most of the 
effectiveness of widely used successful therapeutic antibodies, such as rituximab 
(anti-CD20) and trastuzumab (herceptin, anti-erB2) ! to treat patients with 
lymphoma or breast cancer, respectively ! is based mainly on the cytotoxic 
function of NK cells (Adams and Weiner, 2005; Carter, 2006). Recent in vitro 
data indicate that some cancer cells, especially cancer stem cells, may evade 
ADCC due to the lack of an antibody ligand. The tumor-initiating cells are thus 
spared, and this could explain the clinical relapse and progress of the disease 
(Reim et al., 2009).  
 
NK cells nevertheless lyse targets and function well even in the absence of 
antibodies. Natural cytotoxicity involves a coordinated series of events, starting 
from contact with target cells, tight adhesion, synapse formation, granule 
polarization and granule exocytosis (Orange, 2008). Resting NK cells make use of 
preformed lytic granules to kill target cells. This cytolytic effect is rapid.  
 
Granule release ! perforin and granzymes 
Killing is mediated by cytotoxic molecules which are stored within secretory 
vesicles, specialized exocytic organelles found in NK cells. The cytotoxicity of 
NK cells is executed through the granule exocytosis pathway by which the 
perforin and granzyme B content of granules is released into the immunological 
synapse (IS) after conjugate formation with the target (Lieberman, 2003). 
Granzymes are secreted into a small enclosed space (in IS), and only minute 
amounts of cytolytic material leak out into the extracellular space. During chronic 
inflammation (e.g. rheumatoid arthritis joints) granzyme A can reach low-
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nanomolar levels in extracellular fluids. Normal concentrations in the blood are 
below 1pM (Spaeny-Dekking et al., 1998). The granule content released into a 
single synapse has been estimated to be vastly greater, up to 8µM. The local 
synapse granzyme A concentration is sufficient for lysis to occur, being activated 
at 250nM (Fan et al., 2003; Martinvalet et al., 2008).  
 
The cytotoxicity proceeds in a series of steps: the NK cell first binds the target 
cell, forms a conjugate, delivers a lethal hit and disassociates from the target. 
After the dissociation of conjugates, the NK cell can repeat the same cycle. A 
single NK cell may kill four, or even up to six target cells in 'in a row' (Bhat and 
Watzl, 2007). Interestingly, when NK cells and CTL were studied in target cell 
contacts, the majority of the NK cells showed stepwise and slow cytoskeletal 
polarization, whereas the CTL established cytoskeletal polarization rapidly 
(Wulfing et al., 2003). Furthermore, NK cell killing was particularly sensitive to 
minor disturbances in cytoskeletal dynamics. The authors suggested that the 
stepwise cytoskeletal polarization serves several important checkpoints in NK cell 
killing.  
 
The cytotoxicity of NK cells is mostly mediated by the release of perforin and 
granzyme B. It has been shown that NK cells undergo functional exhaustion after 
killing, leading to a partial loss of perforin and granzyme B. This may be restored 
by IL-2. Furthermore, it has been observed that a single NK cell was able to make 
contact with two or more targets at the same time, but the targets were never killed 
simultaneously. Only very few dead NK cells were detected in conjugates, 
indicating that a great majority of the NK cells was resistant to cytotoxicity. 
Another study showed that about 50% of conjugates between IL-2-activated 
mouse NK cells and NK-sensitive targets were dissociated without killing, 
implicating that conjugate formation without ensuing lysis can occur (Wulfing et 
al., 2003).  
 
4. Target cell recognition 
Target cell recognition induces the formation of a lytic immunological synapse 
between the NK cell and its target. To ensure that NK cells do not kill 
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indiscriminately and are able to distinguish between healthy and diseased cells, 
the entire cytotoxic process is a strictly regulated and highly ordered process.  
 
Target cell recognition can be divided into different processes: 1) binding of 
effector cells to the target, 2) rearrangement of the actin cytoskeleton, 3) forming 
of an activating, lytic immunological synapse, 4) polarization of the microtubule-
organizing centre (MTOC) of the NK cell and the secretory lysosomes towards the 
lytic synapse, 5) docking the secretory lysosomes with the plasma membrane at 
the lytic synapse, 6) fusion of the secretory lysosomes and release of their 
cytotoxic contents, and 7) dissociation of the effector cell from the target (Davis, 
2009). The concept target cell recognition can be defined as regulation of the 
effector cell cytolytic machinery mediated by target-cell-recognizing NK cell 
receptors (Helander and Timonen, 1998).  
 
4.1 Binding to a target !  first requirement, but is it sufficient for 
triggering? 
The adhesion of lymphocytes to other cells and tissues is essential for recognizing 
and killing of target cells, and also for hematopoiesis, communication with APC, 
immune surveillance, and multiple steps of lymphocyte recirculation (Springer, 
1990; Dustin et al., 1992).  
 
LFA-1 on the surface of effector cells 
Target cell binding is the first necessary, but probably not sufficient, step in NK 
cell cytolytic activity. In this process, the integrins and immunoglobulin 
superfamily molecules are crucial (Orange et al., 2003). Leukocyte integrin LFA-
1 is a heterodimeric receptor composed of an integrin alphaL chain (CD11a) that 
associates with an integrin %2 chain (CD18) (Wang and Springer, 1998). LFA-1 is 
expressed on all lymphocytes, granulocytes, monocytes, macrophages and NK 
cells. LFA-1 interacts with ICAMs (ICAM-1 to -5), ligands that are differentially 
expressed on leukocytes, endothelial cells, epithelial cells and fibroblasts 
(Staunton et al., 1989). LFA-1 also regulates leukocyte adhesion to the 




CD18 is the major adhesion structure of fresh, endogenous (unstimulated) NK 
cells. MAbs against CD18 can inhibit T cell proliferation, adhesion of CTL and 
NK cell cytotoxicity (Chen et al., 1987; Timonen et al., 1988). In the absence of 
LFA-1 engagement, seen in patients with CD18-deficient leukocyte adhesion 
deficiency (LAD), target cell lysis by cytotoxic lymphocytes is impaired (Kohl et 
al., 1984). This is also seen in mice with targeted mutations in CD11a or CD18, or 
after blocking of LFA-1 with mAbs (Schmits et al., 1996). NK cells from LFA-1-
deficient mice are unable to kill target cells due to impaired binding capacity 
(Matsumoto et al., 1998). 
 
Matsumoto et al. showed that LFA-1 regulates the cytotoxicity of IL-12-activated 
NK cells against tumor targets, and that the adhesion was impaired in the absence 
of LFA-1. They also studied conjugate formation, and found that LFA-1-mediated 
adhesion seemed to be crucial for NK-mediated cytotoxicity, and that it is 
required to sustain conjugates long enough for interactions between specific 
surface receptors to initiate cytolysis. LFA-1 expression was generally required 
for optimal conjugate formation between cytokine-activated NK cells and target 
cells. LFA-1 thus has an important role in the cytotoxicity of LAK cells 
(Matsumoto et al., 2000). LFA-1 also induces perforin polarization in NK cells. 
 
Barber and colleagues showed that LFA-1 alone was sufficient to initiate 
activation signals in NK cells, in contrast to T cells in which signals from other 
receptors were needed even though adhesion was mediated through LFA-1 
(Barber et al., 2004). It seems that adhesion molecules not only mediate the 
binding but may also act as activating molecules in NK cell killing.  
 
ICAM-2 on target cells 
Currently five intercellular adhesion molecules, ICAM-1!5, are known. They 
mediate cell adhesion by binding to LFA-1. The expression of ICAM-1 is 
sufficient to induce lysis by IL-2-activated NK cells through LFA-1. ICAM-1 
(CD54) is the most widely distributed ICAM; it is found on the surface of 
leukocytes, endothelial cells and other cells (Nortamo et al., 1991). It has been 
shown that the expression of ICAM-1 is up-regulated by several proinflammatory 
cytokines (including IFN-"), and by infection of endothelial and epithelial cells 
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with bacteria and viruses (Shen et al., 1997; Frick et al., 2000). ICAM-1 may also 
act as a signaling molecule, and the expression of ICAM-1 alone is sufficient to 
initiate signal-dependent adhesion on resting NK cells. This adhesion was found 
to be strongly enhanced by either a pulse of IL-2 or IL-15, or the coexpression of 
LFA-3 or CD48 with ICAM-1 on target cells (Holland and Owens, 1997; Barber 
and Long, 2003).  
 
The integrins can be activated by variety of agents, and at least two major 
pathways of activation are known. Activation can be as a result of increasing the 
affinity of the molecule, probably via conformational changes, or by increasing 
the avidity of adhesion, which may result from an increase in the number or 
clustering of integrins in the cell membrane.  
 
ICAM-2 (CD102), like ICAM-1, is relatively broadly distributed in different 
tissues, but low levels are constitutively expressed on most leukocytes, endothelial 
cells and platelets (Nortamo et al., 1991; Diacovo et al., 1994). It seems to be 
involved in lymphocyte recirculation, trafficking, and extravasation (Gerwin et al., 
1999). Other ICAMs have a more restricted expression. ICAM-3 (CD50) is 
present in large quantities on resting lymphocytes, monocytes and granulocytes, 
and is the only ICAM significantly expressed on neutrophils (de Fougerolles and 
Springer, 1992). The expression of ICAM-4 (CD242) is restricted to red blood 
cells, and ICAM-5 (telencephalin) is expressed in the brain (Bailly et al., 1994; 
Yoshihara et al., 1994). All ICAMs may at least partially substitute for each other 
because no disease has been described in which where ICAMs would be absent or 
defective.  
 
CD2!LFA-3 pathway  
Several adhesion molecules participate in the binding of the effector cell to the 
target (Timonen and Helander, 1997). CD2 also activates NK cell cytotoxicity and 
cytokine production, but the function in NK activity may be merely co-
stimulation. Its ligand LFA-3 (CD58), is expressed on the cell surface in both a 
transmembrane and a glycosylphosphatidylinositol (GPI)-anchored form (Dustin 
et al., 1987; Davis et al., 1998). In addition to cell adhesion, CD2 is generally 
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considered to be a costimulatory molecule, and involved in signaling (Springer et 
al., 1987). 
 
Kaizuka et al. recently showed that a native GPI-anchored form of LFA-3 could 
trigger a downstream signaling cascade through the CD2 receptor in the absence 
of TCR (Kaizuka et al., 2009). Interestingly, they further showed that this 
signaling process was accompanied by a dramatic actin-dependent reorganization 
of CD2 and downstream signaling molecules into micro-domains. They found that 
CD2 and TCR were stimulated together, and co-clustered at the cell periphery, but 
segregated from one another near the cell center. They suggested that this local 
cluster of CD2!LFA-3 and TCR together increases the concentration of signaling 
molecules, which can then trigger T cell signaling.  
 
4.2 Triggering of lysis 
It is still uncertain whether adhesion molecules can also function as direct 
triggering receptors. NK cell receptors recognize their ligands on target cells and 
lead to a series of intracellular transduction (Table 1). The different NK receptor-
ligands can activate distinct signaling pathways, including extracellular signal-
regulated kinase (Erk1/2) and c-Jun NH2-terminal kinase (JNK). If the NK-target-
cell conjugate is impaired, the signaling pathway is not activated, and NK cell 
cytotoxicity is inhibited (Table 2). It has been shown, however, that if the signal 
pathways are inhibited and NK cell cytotoxicity is suppressed, the NK-target 
conjugate formation may still remain intact (Zheng et al., 2009).  
 
Because of the multiplicity of receptor-ligand interactions between NK cells and 
target cells, it has been difficult to specify distinct functions to individual 
activating receptors, or to assess the outcome of the simultaneous engagement of 
defined combinations of receptors. It is still not clear which receptors mediate 
signals for adhesion and for granulate exocytosis during natural cytotoxicity, or 
which signaling events are induced by inhibitory receptors, and whether the 
activation receptors differ regarding their sensitivity to inhibition. A recent study 
focusing on the minimal receptor-ligand interactions required to cause natural 
cytotoxicity revealed that strong inside-out signals are induced by a combination 
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of NKG2D and 2B4 or by CD16, which can overcome CD94/NKG2A inhibition 
(Bryceson et al., 2009). 
 
4.3 Immunological synapse ! the time and place of decision 
Almost 30 years ago, long before the immunological synapse (IS) was defined as 
a biological unit, the polarization of the NK cell cytoskeleton and the cell-cell 
contacts were described (Carpen et al., 1982; Carpen et al., 1983). The authors 
analyzed various characteristics of the contact area of human NK cells with a 
target by using scanning and transmission electron microscopy (SEM and TEM). 
They studied cytoskeletal changes in NK cells during conjugate formation, and 
emphasized the importance of a specific cell contact site where cytoskeletal 
proteins were polarized (reorganization of actin and vinculin). Also the 
polarization of the Golgi apparatus towards the contact area was seen after cell-
cell contact.  
 
Table 2.  Defects of the lytic synapse in NK cells from patients with a genetic 
disease. Modified from Orange (2008). 
Disease Protein  Effect on immunological synapse (IS)    
LAD-I  CD18  decreased conjugation with target 
WAS  WASP  decreased F-actin reorganization and integrin distribution 
CHS  LYST  inability to generate normal lytic granules for trafficking to  
the IS 
HPS2 AP3  inappropriate formation of lytic granules and movement  
! subunit  along microtubules 
GS2  RAB27A lytic granules move to the synapse but remain associated  
with microtubules 
FHL3  MUNC13-4 lytic granules move to the IS, but fail to dock and so do 
not achieve an intimate association with the NK-cell  
plasma membrane 
FHL4  Syntaxin-11 lytic granules polarize to and dock at the NK-cell plasma  
membrane but fail to fuse 
             
LAD-I, leukocyte adhesion deficiency type I; CD18, !2-integrin; WAS, Wiskott-Aldrich 
syndrome; WASP, WAS protein; CHS, Chediak-Higashi syndrome; LYST, lysosomal 
trafficking regulator; HPS2, Hermansky-Pudlak syndrome; AP3, adaptor protein 3; GS2, 







Actin is a major cytoskeletal protein. It is extremely well conserved in eukaryotes, 
with little variation in sequence, but due to the great variety of actin-associated 
proteins it plays many roles, from cell shape maintenance to cellular motility 
(Gerwin et al., 1999). In most cells actin is highly concentrated in the immediate 
vicinity of the membrane: the assembly and disassembly of actin are controlled by 
events at the membrane. Controlled polymerization or depolymerization of actin 
filaments is required not only for the production of filaments needed for 
interaction with other components of the cytoplasm, but also for many other kinds 
of cellular activity (e.g. protrusion of membranes, activation, effector functions, 
deadhesion, cell locomotion and migration) (Burkhardt et al., 2008).  
 
Ezrin, a linker protein between plasma membrane and actin 
cytoskeleton 
The ezrin-radixin-moesin (ERM) protein family is a group of highly related 
molecules that participate as linker structures in membrane-cytoskeleton 
interactions (Arpin et al., 1994). Ezrin (first named cytovillin) was independently 
discovered and sequenced at the Haartman Institute, University of Helsinki, and at 
the Cornell University (Bretscher, 1983; Suni et al., 1984). Ezrin is localized in 
microvilli and other cell surface structures (filopodia, membrane ruffles). The 
ezrin gene was located to long arm of chromosome 6 (6q22-q27) (Turunen et al., 
1989; Majander-Nordenswan et al., 1998). It has been shown that in virus 
infections ezrin is redistributed from diffuse localization to newly formed 
microvilli (Pakkanen et al., 1988).  
 
Proteins homologous to ezrin have been discovered: moesin and radixin are 
associated also with cell surface structures and they co-localize with actin (Tsukita 
and Hieda, 1989; Sato et al., 1992). The actin-binding site of ezrin was mapped to 
the COOH-terminal 34 aminoacids of ezrin, and later the same region was 
confirmed as a binding site for moesin and radixin (Turunen et al., 1994; Henry et 
al., 1995; Pestonjamasp et al., 1995). In addition, ezrin has been shown to bind 
cell adhesion molecules CD44, ICAM-1, ICAM-2 and seems to regulate cellular 
adhesion, which is crucial in metastasis (Tsukita et al., 1994; Heiska et al., 1998). 
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Ezrin is expressed in several human tumors, including intestinal tumors, salivary 
gland tumors, renal cell adenocarcinoma and hemangioblastoma (Bohling et al., 
1996).  
 
5. Virus infections and NK sensitivity 
Virus-infected cells produce IFN-$ and -% which induce NK cell proliferation and 
cytotoxicity. NK cells secrete large amounts of IFN-" in response to IL-12 and IL-
18 which are produced during infections by infected cells as well as cells of the 
immune system. Some viruses alter the expression of MHC class I molecules 
quantitatively by directly down-regulating cell surface expression and/or by 
interfering with the ability of IFNs to up-regulate class I molecules (Brutkiewicz 
and Welsh, 1995).  
 
One way to evade the NK-cell-mediated response is by mimicking or blocking the 
MHC molecule (such as CMV, which blocks HLA-E expression) (Kavanagh et 
al., 2001; Lanier, 2008). Human CMV encodes glycoprotein (UL18) which is 
structurally similar to MHC class I, and it affects the NK response by binding to 
the NK inhibitory receptor. These homologs of the MHC class I may serve as 
decoy ligands, allowing the virus to hide from NK cells. However, the activating 
receptor on the NK cell may bind to CMV peptide complex and override the effect 
of the inhibitory receptor, thus leading to NK cell activation.  
 
It has been suggested that the influenza virus hemagglutinin could serve as a 
triggering ligand for NK cells (Mandelboim et al., 2001). The authors showed that 
an activating receptor on NK cells, NKp46, bound to the hemagglutinin of the 
influenza virus, and consequently blocked the killing partially. The other 
activating receptor, NKp30, has been shown to associate with the tegument 
protein pp65 of CMV, but this interaction suppressed the NK cell cytotoxicity 
(Arnon et al., 2005). 
 
The rarity of viral structures in the activation of NK killing was somewhat 
unexpected, since the major biological role of NK cells has been shown to be 



















More specifically  
 
to identify regulatory elements and gene(s) that sensitize target 
 cells to IL-2-activated killer cells, and 
 
to provide a physiological model, i.e. viral infection, to clarify 


















Summary of the Materials and 
Methods 
 
An overview of the materials and methods of this study is presented in the 
following sections, and are all listed in Table 3. More detailed technical 
descriptions (e.g. reagents, antibodies used) can be found in the original 
publications which are referred to by Roman numerals (I-III). One method not 
described in the original articles is presented (unpublished results), and is referred 
to in the original papers listed in the References.  
 
Effector cells (I-III). Several different effector cells and cell lines were used. 
Fresh effector cells were isolated and purified using several techniques. 
Lymphocytes from healthy blood donors were obtained as buffy coats from the 
Finnish Red Cross Blood Service. The cells were isolated by Ficoll-Isopaque 
density gradient centrifugation and filtration through nylon wool columns (PBL). 
NK cells were mainly enriched by Percoll gradient centrifugation (Timonen and 
Saksela, 1980). To isolate different lymphocyte subsets (NK, Th, Ts, T cells) the 
isolated PBL were labeled with mAbs and separated using magnetic beads 
(immunomagnetic cell sorting). CD3-positive T cells were isolated by negative or 
positive selection using CD56 or CD3 coated beads, respectively. When positive 
selection was used, the cells were detached by incubation overnight at +37 °C. 
The other cell subsets were isolated by negative selection; the cells that were 
attached to the beads were removed and the remaining cells were used in the 
assays. The efficiency of the cell isolation was confirmed by flow cytometry 
(FACScan). PBL were incubated with 500 IU/ml rIL-2 overnight to generate the 
LAK activity (LAK cells). Also mouse killer cells isolated from AKR mouse 
spleen were used as effectors in the cytotoxicity assays (both non-activated and 
IL-2-activated cells were used).  
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Target cells (I-III). (I-II) Somatic cell hybrids between mouse (BW5147 or NS-1 
cells) and human lymphocytes were used as target cells. K562 cells served as a 
positive control (NK-sensitive cell line). (III) Infected or transfected HeLa cells 
were used to study the effect of various viral ns-proteins on NK-sensitivity. The 
HeLa cells were grown on cover slips, or on flat-bottom 96-well microtiter plates 
for the cytotoxicity assays. The mock-infected and vaccinia-virus-infected HeLa 
cells served as controls. 
 
Chromosome analysis of mouse/hybrid cells (I-II). For the karyotypic analysis, 
chromosome preparations were stained with a modification of the trypsin-Giemsa 
banding method (Seabright, 1971). Because the karyotypes of the clones are not 
stable and they tend to lose human chromosomes in culture, the chromosome 
preparations were made simultaneously with the functional experiments, i.e. 
binding and cytotoxicity assays. At least 30 cells (metaphases) were analyzed 
from each hybrid cell clone. The hybrids used contained human chromosomes in 
65!90% of the cells. Also the viability of the cells was assessed by the trypan blue 
test.  
 
Chromosomal in situ suppression hybridization, CISS (unpublished). Hybrid 
clones and the parental cells were painted with the human chromosome 6 specific 
probe, and also with the whole human genomic DNA. CISS hybridization was 
performed with biotin-labeled total human genomic DNA and bacteriophage DNA 
library of human chromosome 6 (ATCC LL06NS01) as described by Lichter et al. 
(1988). Prior to the hybridization, the cytoplasm was removed by treating the 
slides with pepsin digestion. The probes were detected by FITC-conjugated 
avidin, and the signals were amplified (Pinkel et al., 1986). Cells were 
counterstained with propidium iodide and DAPI (4´,6-diamidino-2-phenylindole-
dihydrochloride) and mounted in fluorescence antifading buffer (Johnson and 
Nogueira Araujo, 1981). The chromosome painting was performed in 
collaboration with Dr. Marianne Tiainen, University of Helsinki.  
 
Binding assay (I). Effector cells were mixed with target cells and centrifuged, and 
the cell pellet was then resuspended by three gentle aspirations through a Pasteur 
pipette. The cell suspension was pipetted on an objective slide, and the percentage 
of binding lymphocytes and the total number of lymphocytes were immediately 
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calculated by light microscopy. 100 effector cells, regardless of binding, were 
counted and the results were based on 3!8 different experiments.  
 
Cytotoxicity assay (I-III). Target cells were labeled with sodium 51chromium 
(51Cr), washed and incubated with effector cells at three different effector:target 
cell ratios in 96-well microtiter plates. The supernatant from each well was 
collected and the radioactivity was measured in a gamma-counter. For inhibition 
assays the cells were pretreated with mAbs. 
 
Flow cytometry (I-II). To study the level of expression of the surface molecules, 
the cells were labeled with various antibodies, and subsequently incubated with 
FITC-conjugated secondary antibody. Isotype-matched Igs were used as negative 
controls. The fluorescence was determined by FACScan.  
 
Immunofluorescence microscopy (I-III). To study the cell surface expression 
and distribution of an antigen, the cells were incubated with normal rabbit serum, 
washed, incubated with the primary antibody (Ab), and after washing incubated 
with FITC- or TRITC-conjugated secondary Ab. For staining the proteins in 
cytosol, the cells were fixed, permeabilized and treated with primary antibody 
(e.g. human or mouse ezrin, or viral nsP-antibodies; and for visualization of F-
actin the phalloidin was used), followed by FITC- or TRITC-conjugated 
secondary Ab. The nonspecific staining was controlled using the isotype-matched 
immunoglobulins. Also the binding of the secondary reagents in the absence of 
the primary antibody was tested. 
 
Phase-contrast microscopy (II). To study the binding and to visualize the 
effector-target cell conjugates, the LAK cells were mixed with the target cells and 
incubated for 1h. They were then cytocentrifuged gently, analyzed and 
photographed under a phase-contrast microscope.  
 
Immunoblotting (II). For Immunoblotting, proteins separated by SDS-PAGE 
were transferred to nitrocellulose membranes. To study the expression of human 
and mouse ezrin, the human-specific ezrin antibody (CVP1) and the ezrin 
antibody recognizing both mouse and human ezrin (3C12) were used. Human 
JEG-3 cells served as a positive control. 
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Transfection experiments (II-III). (II) Human ezrin cDNA was subcloned into 
the pcDNA3 expression vector and the cells (BW5147, 293) were transfected by 
using DOTAP transfection reagent. To achieve efficient and rapid expression of 
various nsPs, the HeLa cells were first infected with the recombinant vaccinia 
virus system vTF7-3 and then transfected with plasmids containing the desired 
nsP-encoding gene under T7 promoter in pGEM3 using Lipofectin (Fuerst et al., 
1986). Hydroxyurea was used simultaneously with Lipofectin to inhibit vaccinia 
virus DNA replication. Transfection efficiency varied between 80!100%. (III) For 
transient expression of nsP1 under CMV promoter, HeLa cells were transfected 
with nsP1-PC1 plasmid using Lipofectin according to the manufacturer’s 
instructions.  
 
SFV infection (III). HeLa cells were infected with wt SFV using 200 PFU/cell as 
described previously (Laakkonen et al., 1998).  
 
SEM (III). HeLa cells grown on cover slips and then transfected were stabilized 
in the presence of unlabeled phalloidin in a cytoskeleton-stabilizing buffer 
according to Singer et al., and as modified by Sormunen (Singer et al., 1989; 
Sormunen, 1993). The cells were fixed and dehydrated in ethanol and 
hexamethyldisilatzane. Cover slips were coated thinly with platinum and 
examined under a digital scanning microscope. In order to count the number of 
NK cells bound to one target cell, IL-2-activated PBL were added to the target 
cells and incubated for 2 h before fixation.  
 
Statistical analysis (I-III). Mean values and statistical differences were 
calculated from the results of 3 to 21 experiments (i.e. different lymphocyte 
donors). Values were calculated with parametric two-tailed Student’s test in order 
to show differences in the binding or cytotoxicity of effector cells from the same 
donor. The non-parametric Mann-Whitney U test was used to compare different 
donors. In addition, several experiments were conducted because of the variation 







Table 3. The materials and methods used in this study. 
 




PBL, LAK       I-III 
NK        I-III 
T, Ts, Th       I 
mouse killer cells (from AKR mouse spleen)  II 
Target cells 
human/mouse hybrid clones  I-II 
BW5147  (AKR mouse thymoma)   I-II 
NS-1  (BALB/c myeloma)     I 
K562  (chronic myelogenous leukemia)   I-II 
293  (human embryonic kidney-derived cells)  II 
JEG-3  (human choriocarcinoma)    II 
HeLa  (cervix carcinoma)      III 
 
Methods 
Isolation of lymphocytes     I-III 
Cell cultures        I-III 
Chromosome analysis     I-II 
Chromosomal in situ suppression hybridization   unpublished 
Binding assay      I-II 
51Cr-release cytotoxicity assay    I-III 
Competition experiment     I 
Blocking of effector cell functions    I-III 
Cell transfection      II-III 
Cell infection (VV, SFV)     III 
Immunofluorescence microscopy    II-III 
Flow cytometry      I-II 
Immunoblotting      II 
Scanning electron microscopy (SEM)   III 
Statistical analysis      I-III 












Results and Discussion 
 
The Roman numerals refer to the original publications. 
 
1. IL-2-activated NK cells and human chromosome 6 (I) 
 
1.1 Mouse/human cell hybrids as target cells 
At the time when this study was initiated very little was known about the target 
structures recognized by NK cells. We studied the differences and capacity of 
unstimulated and IL-2-activated NK cells to bind and kill target cells, and used 
mouse/human hybrid cells containing various human chromosomes as targets. 
Hybrid cells have earlier been used successfully as a tool for assigning human 
genes (gene mapping) to human chromosomes. We analyzed several hybrid clones 
(‘karyotyped’ human chromosomes) containing from one single human 
chromosome to eleven different human chromosomes. The human genomic 
material on the hybrids and parental cells was further verified by chromosomal in 
situ suppression hybridization (CISS) method. The 6-hybrid cells contained one or 
two human chromosomes number 6 per cell (in at least 80% of cells). Parental 
cells were negative for both chromosome 6-specific and total human DNA probes 
(Fig. 2). 
 
1.2. Binding of non-activated and IL-2-stimulated PBL to mouse/human 
hybrid cells 
The percentage of effector cells that bound to target cells was analyzed. The 
binding of unstimulated PBL to hybrid cells was only slightly more effective than 
the binding to the mouse parental cells. However, about 30% to over 50% of the 
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LAK cells were bound to human chromosome 6 containing hybrid cells, compared 
to parental cells or hybrid clones having other than number 6 human 
chromosomes. Furthermore, the number of NK cells binding to the 6-hybrids was 
the same (or even higher) as that binding to K562 cells, which are known as NK-
sensitive target cells and are usually used as a positive control in many (especially 
cytotoxicity) assays.  
 
A  mouse/human 6-hybrid cells        B  BW5147 mouse thymoma  
  
C               D 
  
Figure 2. 6-hybrid clones (A, C) and parental cells (BW5147; B, D) painted (yellow) with 
biotinylated chromosome 6-specific library probes (A, B) and with total human genomic 
DNA (C, D).  
 
To discover which subpopulation of lymphocytes binds to human chromosome 6 
hybrid cells, the various lymphocyte subsets were used as effectors against the 
hybrid clones. Chromosome 6 was the only human chromosomal material in the 
6-hybrid clones used as targets. Almost the same number of unstimulated NK 
cells, as of unstimulated PBL, was bound to target 6-hybrid cells. However, when 
activated by IL-2, 56% of the NK cells were bound to human chromosome 6 
hybrids, whereas significantly fewer T cells were bound (only half of the number 
of NK cells; the subsets of T cells were bound at the same level as when they were 
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non-activated). It seems that mainly NK cells were responsible for LAK cell 
binding to chromosome 6-hybrid cells.  
 
1.3 Cytotoxicity of non-activated and IL-2-stimulated PBL to 6-hybrid 
cells 
In line with the results on binding, the unstimulated PBL killed hybrids or parental 
cells only weakly. In contrast, the hybrid cells were very effectively lysed by IL-
2-activated killer cells. Even at the effector:target ratio 15:1 almost half of the 
hybrid cells were killed in a 3-h chromium release assay. Unstimulated T cells 
bound to the 6-hybrids, but were not able to lyse them at the same level as NK 
cells even after being activated by IL-2. NK cells effectively bound to and lysed 
the 6-hybrid cells. In other words, human chromosome 6 must encode genes 
important for IL-2-activated NK cell binding and cytotoxicity. 
 
Because both the 6-hybrids and K562 cells were effectively bound to and killed 
by IL-2-activated NK cells, we wanted to find out whether different recognition 
mechanisms (structures) were involved in the killing of these two targets. We 
conducted a competition assay in which K562 cells compete with the 6-hybrid 
cells. We observed that K562 cells inhibited the 6-hybrid killing suggesting that 
K562 and 6-hybrid cells possibly share the same structures recognized by IL-2-
activated NK cells. 
 
1.4 Expression of human MHC class I and II antigens 
It has been shown that the expression of human MHC class I antigens is central in 
NK response. The down-regulation of HLA antigens, e.g. as a result of viral 
infection, activate NK cell killing, whereas the increased expression of MHC class 
I inhibits NK activity. The human MHC cluster is located on the short arm of 
chromosome 6 (6p21). All hybrid cells carrying human chromosome 6 expressed 
both MHC class I and class II molecules. Our data thus imply that there may be 
other molecules that override the effect of the MHC inhibition.  
 
Our group has demonstrated that the receptors involved in binding IL-2-activated 
NK cells to colon carcinoma cells were LFA-1 (CD11a-c/CD18) and CD2, CD54 
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and RGD-peptide-containing structures (Timonen et al., 1990). However, these 
could not be the target structures encoded on chromosome 6 since their genes are 
localized elsewhere. Also the other CD11/CD18 ligands were considered to be 
unimportant because these adhesion ligands seem to play only a minor role in IL-
2-activated killing. 
 
Also the gene for TNF-$ is assigned to human chromosome 6 and is known to be 
important in NK cell killing. We cultured the parental cells with exogenous TNF-
$ to study whether this would increase binding and/or sensitivity. Parental cells 
were not sensitized to LAK cells in the presence of TNF-$. 
 
Interestingly, it has earlier been shown that the introduction of a single human 
chromosome 6 into a human melanoma cell line (by microcell fusion) reduces the 
tumorigenicity of these cells in nude mice (Trent et al., 1990). The authors 
suggested that the genes in chromosome 6 suppress the malignant phenotype. One 
may speculate that the more benign phenotype may at least partially be due to the 
increased NK sensitivity of melanoma cells.  
 
We conclude that human chromosome 6 sensitizes NK-resistant mouse cells to 
NK activity, and suggest that chromosome 6 contains gene(s) encoding either 
target ligands or regulatory molecules that control the expression of target ligands 
for IL-2-activated killer cells. 
 
2. ICAM-2 and cytoskeletal ezrin in NK cell activity (II) 
2.1 Adhesion molecules  
The central receptor-ligand pairs in cell adhesion between target and effector cells 
are LFA-1!ICAMs and CD2!LFA-3. The effector cells were pretreated with 
mAbs against LFA-1 $-chains, CD11a, b, and c, and CD18 (%-chain) to inhibit the 
killing. The cytotoxicity was effectively blocked by CD11a and CD18 mAbs 
(present on killer cells). Also the mAbs against mouse ICAM-2 (the LFA-1 ligand 
present on target cells) inhibited killing. Other mAbs against the $-chains 
(CD11b!c) did not block the cytotoxic effect, showing that the CD11a/CD18-
ICAM-2 pathway seems to be crucial in the recognition of chromosome 6 cell 
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hybrids by IL-2-activated killer cells. Also the activated murine killer cells that 
were isolated from AKR mouse spleen lysed the 6-hybrid cells, whereas the 
parental cells were resistant.  
 
2.2 Expression and distribution of mouse ICAM-2, and cell polarization 
Regulating the level of expression is one way to impact the function of the 
molecule. We studied the expression of mouse ICAM-1 and -2 by flow cytometry. 
The 6-hybrid and parent cells expressed equal levels of mouse ICAM-2. However, 
the distribution of mouse ICAM-2 on the cell surface was different: ICAM-2 was 
evenly distributed in NK-resistant mouse cells, but was strongly polarized in NK-
sensitive 6-hybrid cells. Furthermore, 6-hybrids differed morphologically, because 
they had a prominent uropod (bud-like extension) on the tip of which almost all 
ICAM-2 expression was concentrated. The parental cells lacked these extensions. 
ICAM-1, another ligand of the CD11a/CD18 molecule, was evenly distributed in 
both cell lines.  
 
The results show that ICAM-2 was redistributed in mouse BW5147 cells as a 
result of the introduction of human chromosome 6. Phase contrast microscopy 
revealed that 70% of the conjugates were uropod-associated. This indicates that 
the majority of IL-2-activated killer cells recognize structures expressed on the 
uropods. The ICAM-2 appears to have a key role in recognition, because ICAM-2 
antibodies inhibited the cytotoxicity of the 6-hybrids. The redistributed ICAM-2 
seemed to be involved in the recognition of the 6-hybrids by IL-2-activated killer 
cells. 
 
2.3 Colocalization of membrane-cytoskeletal linker protein ezrin and 
ICAM-2 
It is evident that chromosome 6 must carry genes that are important in sensitizing 
hybrid cells to IL-2-activated killing, and that ICAM-2 is a target structure in this 
process. However, the gene of ICAM-2 is assigned to human chromosome 17 
(17q23-q25). So it is likely that there could be some regulating elements, encoded 
by genes located in chromosome 6 that are essential in the redistribution of 
ICAM-2.  
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It is known that the cytoskeleton has a central role in the topography of surface 
molecules. ERM family members act as molecular linkers between the cell surface 
protein CD44 and actin-based cytoskeleton (Arpin et al., 1994; Tsukita et al., 
1994). The gene of one member of the ERM family, ezrin, has been localized on 
the long arm of human chromosome 6 (6q22-q27), and it has been proposed to act 
as a membrane-actin cytoskeleton linker (Turunen et al., 1989; Algrain et al., 
1993; Majander-Nordenswan et al., 1998). Immunoblotting showed that both the 
6-hybrid and parental cells expressed mouse ezrin. Furthermore, 6-hybrid cells 
expressed also human ezrin, which was verified using specific human ezrin 
antibodies. Analyzing the expression of ezrin by immunofluorescence microscopy 
revealed that the expression was similar to that of ICAM-2: also ezrin was 
localized to uropods in 6-hybrids, and was evenly distributed in parental cells 
(distribution of F-actin and ezrin, Fig. 3). When cytochalasin B was used to 
disrupt the F-actin cytoskeleton, the uropods and concentrated expression of 
ICAM-2 disappeared (data not shown).  
 
A mouse/human 6-hybrid cells         B BW5147  
  
C               D  
  
Figure 3. Localization of F-actin (phalloidin) (A-B) and ezrin (C-D) in 6-hybrids (A, C) and mouse 
parental, BW5147 cells (B, D). Note the prominent uropods in 6-hybrid cells where almost all 
actin and ezrin is concentrated. 
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These results suggest that the distribution of ICAM-2 is controlled (regulated) by 
the cytoskeleton, and ezrin plays a key role in redistribution cell-surface 
molecules into the newly formed cellular protrusions. Presently, a uropod is 
defined as a plasma membrane protrusion in which specific organelles, 
cytoskeletal proteins, adhesion and signaling receptors are concentrated (Sanchez-
Madrid and Serrador, 2009).  
 
2.4. Ezrin regulating the cellular distribution of ICAM-2 and NK 
sensitivity 
Human ezrin was transfected to NK-resistant cells in order to clarify the role of 
ezrin in ICAM-2 redistribution and NK sensitization. The cell morphology of 
ezrin-transfected cells was very similar to that of the 6-hybrid cells: The 
transfected ezrin induced uropod formation, redistribution of ICAM-2 into the 
uropods, and human ezrin was colocalized with ICAM-2 in these (newly formed) 
uropods. In cytotoxicity assays, the ezrin-transfected cells were sensitized to IL-2-
activated killing. It was thus evident that ezrin was the key player in the 
redistribution of ICAM-2 and the sensitization of 6-hybrid cells to IL-2-activated 
killer cells ! especially to activated NK cells, which had already been shown ! to 
be the main cell subset responsible for the killing of 6-hybrid cells.  
 
In transfected BW5147 thymoma cells, ezrin is appears to be in active form 
(perhaps due to phosphorylation) and therefore polymerizes with other ezrin 
molecules and/or other members of the ERM family. The polymerization of ezrin 
leads to uropod formation and the reorganization of ICAM-2. The increased local 
concentration of ICAM-2 creates sufficient avidity for the %2-integrin-ICAM-2 
pathway to operate in target cell recognition.  
 
The sequence of binding and triggering in NK killing was previously thought to 
start by signaling through triggering receptors, analogous to T cell recognition. 
This would then lead to conformational changes in adhesion molecules, 
facilitating binding and enhancing triggering. Our model shows that effector cell 
binding to a target cell is not a secondary, non-selective, and merely supportive 
phase. Probably the conformational change in CD11a/CD18 is induced by the 
presence of IL-2 and not by triggering receptors. Our results do not determine 
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whether the CD11a/CD18!ICAM-2 is also the triggering pathway in NK cell 
killing.  
 
Also the membrane distribution of CD44, CD45, MHC class I, ICAM-1 and LFA-
3 (all against mouse antigens) on the 6-hybrids was studied (Table 4). No 
redistribution of CD45, and only marginal redistribution of CD44, MHC class I, 
ICAM-1 and LFA-3 was seen (the distribution of MHC class I, ICAM-2 and 
CD45 in Fig. 4). Blocking antibodies against these molecules did not inhibit 
cytotoxicity, and clearly the redistribution of ICAM-2 was most impressive both 
morphologically and functionally. It has not yet been shown that MHC I would 
associate with ezrin or actin. Indeed, our data show that MHC class I does not 
colocalize with ICAM-2 into cellular projections (Fig. 4). It seems that a cell may 
become sensitized to NK cytotoxicity as a result of alterations in the membrane 
topography, and not only after quantitative down-regulation of self-MHC class I. 
 
Table 4. Expression and distribution of mouse cell surface antigens on NK-
sensitive 6-hybrid cells.  
 
Mouse molecule   Expression    Redistribution   
ICAM-1      ++    + 
ICAM-2      ++            +++ 
MHC class I (H-2)     ++    ± 
CD44         +    + 
CD45        +    - 
LFA-3 (CD58)      +    - 
            
Levels:  +++ strong,  + moderate,  ± marginal/weak,  - no redistribution.  
 
 
These data reveal a novel form of NK cell recognition: target structures are already 
present on normal cells; they become detectable only after abnormal redistribution 








A mouse MHC class I        B  mouse ICAM-2  C  mouse CD45 
   
Figure 4. NK-sensitive target cells (6-hybrids) stained with antibodies against mouse 
cell surface antigens. Expression of MHC class I (H-2) (A) and CD45 (C) are evenly 
distributed on the cell membrane, but ICAM-2 (B) is redistributed in the tip of the cellular 
extensions (uropods) making the local concentration sufficient for NK cell recognition. 
 
3. Viral early protein nsP1 in NK cell killing (III) 
3.1 Background 
NK cells are known to effectively lyse virus-infected cells. The virus-proteins that 
directly activate human NK cell killing are largely unknown. Because NK cells 
are crucial in the clearance of especially herpes viruses, this particular virus would 
provide an optimal biological model for studying the reorganization of adhesion 
molecules and ezrin in the regulation of NK sensitivity. NK-resistant cell lines 
were infected with various HSV-1 mutants (viruses with different genomic 
deletions) in order to investigate the viral gene(s) that would be crucial in 
sensitizing the target to NK cell killing. Unfortunately, the HSV, being a rather 
large and complex double stranded DNA (dsDNA) virus, rendered the 
experiments and investigations cumbersome. Despite considerable efforts to try to 
screen virus mutants (several HSV genes were deleted) in adhesion and 
cytotoxicity, the results were not sufficiently consistent to enable us to continue 
with this virus.  
 
3.2 Viral non-structural proteins translated early in the virus cycle  
The sensitivity of virus-specific early proteins of Semliki Forest virus (SFV) to NK 
killing was studied. SFV offers a good model for studying the sensitization of virus-
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infected cells to NK lysis. This is because SFV infects a large variety of cell types, 
the whole genome has been sequenced, and the infection cycle is well characterized.  
Semliki Forest Virus 
SFV belongs to the alphaviruses and is among the simplest enveloped viruses. 
They are single-stranded RNA viruses (ssRNA; about 11.5 kb) which are able to 
cause lifelong infections in invertebrates, and acute usually transient infections in 
vertebrates (i.e. encephalitis and fever). They can cause severe cytopathic changes 
in mammalian cells: host cells die within 20 h post infection (p.i.). From 3!5 h 
after infection, the host cell DNA, RNA and protein synthesis are inhibited. The 
RNA replication of SFV is directed by four viral nonstructural proteins (nsP1!4). 
The replication takes place entirely in the cytoplasm of the host cell in association 
with smooth membranes (in distinct vesicular structures: some of these are called 
cytoplasmic vacuoles or modified endosomes and lysosomes). Nonstructural 
proteins are most actively translated early in infection, and host cell DNA, RNA 
and protein synthesis are severely inhibited already 3!5 h p.i. It seems that 
nonstructural proteins are sufficient for the inhibition of host protein synthesis, but 
other functions are needed for rapid cytopathic changes.  
 
Nonstructural proteins of SFV 
Viral replication depends entirely on four nonstructural proteins (nsP). To study the 
effect of virus-specific genes translated early in the virus cycle, the four nonstructural 
proteins of SFV were separately transfected to HeLa cells, which were used as targets 
for NK cells. Nsp1 is an mRNA capping enzyme (formation of the cap at the 5’ 
terminus of the viral mRNA molecules); it is membrane-associated with the 
cytoplasmic side of the plasma membrane, endosomes and lysosomes. The capping of 
viral RNA is thought to be mediated by the viral proteins (the enzymes responsible 
for the cap formation on the cellular mRNAs are in the nucleus). NsP1 is needed for 
the initiation of minus strand synthesis; it occurs early in infection and ends about 3!
4 h p.i. Interestingly, it has earlier been found that nsP1 induces numerous surface 
extensions (filopodia) and causes rearrangement of actin filaments (Laakkonen et al., 
1998). These extensions contained nsP1 along the whole length of the filaments. The 
phenomena occur in virus-infected cells and seem to be a common cellular response, 
at least to alphavirus infections.  
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NsP2 is responsible for the processing of non-structural proteins, and 50% of the 
nsP2 molecules are transported to the nucleus, with specific enrichment to the 
nucleoli. This may inhibit host DNA synthesis (Peranen et al., 1990). NsP3 is a 
phosphoprotein, but no specified function for it has yet been found (Vasiljeva et 
al., 2000). It appears to be essential for virus replication and may participate in the 
membrane association of the replication complex (Peranen et al., 1988; Vihinen et 
al., 2001). NsP4 appears first, but is nevertheless the last to be translated. It is a 
polymerase subunit and interacts with host components, modulating viral RNA 
replication.  
 
To express the various nonstructural proteins in HeLa cells, the recombinant vaccinia 
virus expression system was used. With it, a high transient expression of proteins 
could be achieved for a short time. The replication of vaccinia virus itself was 
inhibited. We investigated whether a similar mechanism might be involved in NK 
sensitization in virus infection as the one we had shown earlier with the mouse/human 
hybrid model.  
 
3.3 Viral replicase protein nsP1 sensitizes targets for NK activity 
Our results show that nsP1-transfected cells were very effectively killed by IL-2-
activated lymphocytes. Almost 60% of nsP1-transfected cells were lysed, whereas 
only about 35% of the controls were killed (untreated or vaccinia virus-infected 
cells). The sensitivity of other nsPs (nsP2!4) to NK killing was similar to the 
controls. The infection of HeLa cells with the whole virus proved to be as sensitizing 
to NK cell killing as the transfection of nsP1 gene alone. Unstimulated PBL, even in 
quite small numbers, killed nsP1-transfected cells statistically significantly more 
effectively than control cells. 
 
3.4 Deletion of membrane-binding properties of nsP1 inhibited the killing 
Since the virus replication seems to be membrane-associated, and nsP1 is tightly 
associated with the cytoplasmic surface at the plasma membrane, the mutated 
nsP1 construct lacking the membrane-binding properties was transfected to the 
targets. Mutated nsP1 did not induce any microvilli or filopodia-like extensions, 
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and the cells were not lysed by IL-2-activated NK cells. As known, cytochalasin 
D inhibited the polymerization of actin filaments, resulting in the disappearance of 
actin fibers and the appearance of actin aggregates in the cytoplasm (Flanagan and 
Lin, 1980). 
 
3.5 Binding of NK cells to nsP1 induced filopodia-like structures 
We studied the binding of IL-2-activated NK cells to the targets using SEM (and 
TEM, results not shown). Early (2h) after nsP1 transfection, thin filopodia were 
seen on the cell surfaces and few NK cells were bound to the targets. Later (6h) 
after nsP1 transfection, longer and protruding extensions were seen in target cells, 
and numerous NK cells were attached to these structures. Modest or no binding 
was seen in the controls, and a maximum of four NK cells were seen in only two 
control target cells. However, many nsP1-transfected cells were so abundantly 
covered with NK cells that the counting of binding cells was impossible. This was 
never seen in control cells.  
 
NK cells were bound only to cells with numerous microvilli and extensions (Fig. 
5). Other nsP-transfected (or mutated nsP1) and control cells either lacked or had 
very few filopodia-like structures. Also the morphology of NK cells attached to 
nsP1 transfectant had drastically changed from round cells to ones containing 
large cellular projections, uropods and microvilli (Fig. 5). 
 
A      B  
  
Figure 5. Binding of NK cells to nsP1 transfected HeLa cells analyzed using SEM. Note 
numerous microvilli and long cellular extensions on target cell surface (A), and also 




3.6 The CD2!LFA-3 pathway in nsP1-induced NK killing 
The main adhesion molecules in NK cell killing of SFV-infected cells were 
studied. As observed earlier, the CD11a and CD18 antibodies effectively blocked 
the killing of the 6-hybrids. However, CD18 (%-chain of CD11/CD18 complex) 
did not affect the killing of the nsP1-transfected cells. In contrast, the cytotoxicity 
of nsP1-transfected cells was strongly inhibited by CD2 antibodies, suggesting the 
importance of its ligand LFA-3 on the target cells. Because CD2 antibodies 
effectively blocked the killing, it is possible that LFA-3 may function as key target 
molecule. We could not verify the expression (or possible redistribution) of LFA-
3. It was difficult to detect any adhesion molecules on nsP1-transfected cells, 
probably due to numerous overlapping treatments. It can nevertheless be 
speculated that also LFA-3 may redistribute on the surface of a target cell, where 
ezrin can interact with nsP1 and act as a linker between LFA-3, nsP1 and the actin 
cytoskeleton. 
 
3.7 Colocalization of nsP1 and ezrin 
We studied the expression and distribution of membrane cytoskeleton linker 
protein ezrin in NK-sensitive nsP1 transfected cells. The controls and nsP1-
transfected cells expressed ezrin, but its distribution was concentrated in the 
cellular extensions in nsP1-transfected cells. Ezrin was distributed along the entire 
length of filopodia-like structures to which the NK cells were usually bound. The 
tight membrane association of nsP1 (and localization in membrane projections) is 
central in NK sensitivity because other ns-proteins that remained in the cytosol 
(and were not membrane-bound) did not enhance killing. About 80% of NK cells 
were bound to nsP1-transfectants 6 h post-transfection. Untransfected or vaccinia-
virus-infected cells nor other nonstructural proteins nsP2, -3 or -4 seem not to 
induce NK killing. However, it is notable that the killing of nsP3-transfected cells 
was slightly increased compared to other nsPs or controls. This might have been 
due to weak membrane-binding properties of the protein. When the membrane 
association was disrupted (mutated nsp1 transfectants) the cellular projections 




We have shown that virus-specific, early-translated protein in the virus cycle 
sensitizes infected cells to NK activity. Early viral replicase protein may interact 
with (redistributed) cytoskeletal linker protein ezrin in filopodia-like structures 
that are induced by membrane-associated nsP1. NK cells are strongly bound to 
these extensions and efficiently recognize and kill the early viral nsP1-producing 
target cells.  
 
It is thus possible that early translated nonstructural proteins in the virus cycle, 
such as nsP1, mediate NK sensitization via relocalized cytoskeletal proteins. The 
adhesion molecule may serve as a target molecule, perhaps overriding inhibitory 
signals. This sensitization occurs early in infection, long before any structural 
viral proteins are produced. In accordance with this view, it is known that HSV-
infected cells become NK-sensitive long before the actual (structural) viral 
proteins are expressed on the surface of infected cells (Orange et al., 2002; 
Carayannopoulos and Yokoyama, 2004; Mossman and Ashkar, 2005; Sun and 
Lanier, 2009). 
 
To conclude, NK cells probably screen the environment continuously, and may 
react instantly to early conformational and topographical changes in the plasma 
membranes of virus-infected cells. It is likely that this recognition not only leads 
to target cell lysis, but also to cytokine production, which in turn facilitates and 














NK cells were initially described as potent effector cells of the innate immune 
system, which, unlike T cells, are able to kill targets without specific recognition 
mechanisms. Recently, NK cells have been shown to exhibit characteristics of 
adaptive T cell responses. It seems that NK cells have the capacity for 
immunological memory (Cooper et al., 2009). A certain NK cell subset can 
produce IL-22 which earlier was regarded to be solely a helper T cell cytokine 
(Cella et al., 2009). Furthermore, differentiation of NK cell subsets seems to occur 
also in the thymus and lymph nodes, which are traditionally organs of the adaptive 
immune system (Hughes et al., 2009).  
 
NK cells seem to act in both innate and adaptive immune responses. It is also 
becoming more evident that NK cells are not, as proposed earlier "non-MHC-
restricted" killer cells, but rather screen the MHC status of potential target cells.  
 
The results of the present study show that NK cells screen alterations in the 
distribution of cell surface structures. Target structures are not foreign (e.g. viral) 
compounds, but topographically redistributed normal cellular proteins that make 
the local concentration sufficient for recognition. These newly formed "hot spots" 
may alter the spatial relations of inhibitory and activating ligands. The balance is 
controlled by the cytoskeleton. The topographical alterations resemble pattern 
recognition, a phenomenon common in innate immunity. 
 
Based on the results of this thesis, a new model of target cell recognition of NK 
cells can be suggested: reorganization of the cytoskeleton induces alterations in 
cell surface topography, and this new pattern of surface molecules is recognized 











In the present model, the data do not distinguish whether the target cell 
recognition is merely adhesion but also triggering. A simple explanation would be 
a relative reduction of inhibitory MHC class I molecules on the tip of the cellular 
extensions may be sufficient for the triggering via the adhesion bridge. Although 
signal transduction may be activated through traditional adhesion pathways, NK 
triggering is a complex phenomenon, and involves several mechanisms. 
Regardless of the still unknown details behind the triggering, the present results 
suggest that a treshold element is the proportion in the spatial expression of 
inhibitory MHC class I and triggering ligands. A change in their balance probably 
plays a key role in determining the fate of the cells under the screening 
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